Kyongbo Pharmaceutical

Kyongbo Pharmaceutical, established in 1987 as Korea's first dedicated active pharmaceutical ingredient (API) manufacturer, listed on the KOSPI in 2015 and is 43.41% owned by Chongkundang Holdings, the group's holding company. The business consists of two pillars: API and finished dosage products.

The API segment produces general API, cephalosporin-class antibiotic API, and oncology/high-potency API, exporting to countries including China and Italy.

The finished dosage segment covers cardiovascular, anesthesia/pain, and gastrointestinal prescription drugs along with over-the-counter products, with the non-narcotic combination pain injection 'Maxigesic' emerging as a key growth driver.

While API historically accounted for more than 60% of revenue, the finished dosage share has steadily expanded, diversifying the business mix. The company has also diversified into medical devices and animal health/nutritional products.

The most significant recent shift is the structural transition from a traditional chemical-synthesis API company toward an antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO).

A dedicated ADC GMP facility spanning preclinical through commercial production is being built at the Asan plant, complemented by a separate Yongin ADC research center developing linker-payload synthesis and conjugation technology in-house.

In terms of competitive positioning, Chong Kun Dang Bio and ST Pharm operate similar businesses in the API space, while LegoChem Biosciences and Binex form part of the domestic competitive landscape in ADC CDMO.

Consolidated revenue reached a record 264.1 billion won in 2025, up 10.7% from 238.6 billion won in 2024, but operating profit plunged 66.3% to 3.52 billion won from 10.45 billion won, with operating margin falling sharply from 4.4% to 1.3%.

Net income attributable to owners was just 182 million won, down 97.1% from 4.64 billion won the prior year, reflecting intensifying R&D spending and the burden of new ADC business investment.

Looking at the most recent four quarters (2025Q3 through 2026Q2), revenue held a gentle growth trajectory at 67.0 billion won, 71.2 billion won, 66.1 billion won, and 75.2 billion won respectively, while quarterly operating profit ranged narrowly between 470 million and 930 million won, notably lower than prior periods.

Net income showed considerable volatility, swinging to losses of 1.72 billion won in 2025Q2, 430 million won in 2025Q4, and 530 million won in 2026Q1, before returning to profits of 3.03 billion won in 2025Q3 and 2.97 billion won in 2026Q2.

This contrasts with the steady recovery trend from 2022 to 2024, when revenue grew from 196.3 billion to 238.6 billion won and operating profit climbed from 1.39 billion to 10.45 billion won.

Operating cash flow improved to 7.46 billion won in 2025 from just 149 million won in 2024, though it remains below the 10.13 billion won recorded in 2022. The debt ratio rose from 67.4% in 2022 to 119.3% in 2025, signaling growing financial burden tied to ADC facility investment.

The domestic API industry in Korea suffers from low self-sufficiency in raw materials used for finished drug production, resulting in structural dependence on imports, which makes export expansion and migration toward higher value-added products a key challenge for domestic API companies.

The global trend is shifting from simple API synthesis toward high-difficulty synthesis, customized production, CDMO, and materials for next-generation modalities such as antibody-drug conjugates (ADC).

The ADC market is rapidly moving into clinical and commercialization stages; Eugene Investment & Securities analyst Kwon Hae-soon stated that "ADC CDMO is an area expected to see solid growth alongside global clinical trends, particularly the expansion of combination therapies,

Kyongbo disclosed its 2026 value enhancement plan, presenting completion of the ADC plant, expansion of AI-based workflows, and global ESG regulatory response projects as its three key goals.

The Asan ADC GMP production facility targets completion by end-2026, followed by facility validation and GMP certification through the third quarter of 2027, with full-scale clinical sample production planned thereafter.

Production capacity for the first line is estimated at around 125 kg per year of drug substance (DS) and 1.25 million vials per year of drug product (DP), with a structure allowing further expansion through a second phase of investment.

Securing a 20 billion won low-interest loan from the National Growth Fund adds policy financing support that partially eases the investment funding burden.

In the finished dosage segment, the non-narcotic analgesic 'Maxigesic' remains a core growth driver, with observers noting that Belgian firm Hyloris's FDA approval of 'Combogesic IV' in the US has laid the groundwork for global expansion.

In the API segment, the US FDA's VAI rating for the Asan facility has opened a pathway for US market entry for fifth-generation cephalosporin antibiotic 'ceftobiprole' and oncology drug 'lenalidomide' API.

However, since many ADC pipelines remain in clinical stages, delays or failures in client development programs could postpone CDMO demand generation, and early-stage depreciation burdens and utilization shortfalls also present potential delays to monetization.